Skip to main content
Let's spread the word about Immunotherapy! Click to share this page with your community.

Cancer Research Institute Wins $1 Million from Revlon for Women’s Cancers

November 07, 2016

Cancer Research Institute's staff celebrating first place

We are thrilled to announce the Cancer Research Institute's FIRST PLACE finish in the Revlon LOVE IS ON Million Dollar Challenge. After coming in second place in the 2015 competition, CRI is honored to have been declared this year’s winner and the recipient of the $1 million grand prize.

More than 100 charitable organizations that focus on women’s health participated in this year’s Million Dollar Challenge. The challenge, which launched September 14, inspired the spirit of giving as well as the spirit of competition; participating charities raised more than $6 million dollars over the six-week campaign.

“The Cancer Research Institute is honored to win the 2016 Revlon LOVE IS ON Million Dollar Challenge in support of immunotherapy research for women’s cancers,” said Jill O’Donnell-Tormey, Ph.D., CEO and director of scientific affairs for the Cancer Research Institute. “We are inspired by the generosity of our donors, Revlon, and Crowdrise, which hosted the online event, and hope that together, we can achieve enduring cures for all cancers in the near future.”

With donor support, we raised more than $1.2 million dollars, making us the top fundraiser in the competition and securing our place as winner of the $1 million grand prize. CRI will dedicate the full proceeds of this campaign—more than two million dollars—to funding lifesaving cancer immunotherapy research for all cancers, including breast, lung, and colorectal cancers, the top three worldwide causes of cancer deaths in women.

We are grateful to Revlon and Crowdrise for the opportunity to be part of such a unique campaign for the second year, and humbled by the remarkable generosity of our donors. Thank you all for showing your love for the Cancer Research Institute!

Be in the know with the latest immunotherapy news

*Immunotherapy results may vary from patient to patient.

Top